Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15376451 | 0.89 | SMN1; SMN2 (0.40) | ALDH1A1MAPK1LMNACA12CA1 | |
| SCHEMBL2224391 | 0.85 | ALDH1A1 (0.57) | ALDH1A1MAPK1LMNACA12CA1 | |
| SCHEMBL28774060 | 0.85 | ALDH1A1 (0.57) | ALDH1A1MAPK1LMNACA12CA1 | |
| SCHEMBL25363482 | 0.85 | ALDH1A1 (0.57) | ALDH1A1MAPK1LMNACA12CA1 | |
| SCHEMBL316646 | 0.80 | ALDH1A1 (0.49) | ALDH1A1MAPK1CA12CA1CA2 | |
| SCHEMBL2878783 | 0.80 | ALDH1A1 (0.49) | ALDH1A1MAPK1CA12CA1CA2 | |
| SCHEMBL2880648 | 0.80 | ALDH1A1 (0.49) | ALDH1A1MAPK1CA12CA1CA2 | |
| SCHEMBL2573409 | 0.80 | ALDH1A1 (0.35) | ALDH1A1MAPK1LMNACA12CA1 | |
| SCHEMBL30793930 | 0.79 | ALDH1A1 (0.51) | ALDH1A1MAPK1LMNAGLAHSD17B10 | |
| SCHEMBL4513401 | 0.79 | ALDH1A1 (0.41) | ALDH1A1MAPK1LMNACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738633-B2 | Cognition enhancing compounds and compositions, methods of making, and methods of treating | NEUROSOLIS, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160340348-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | MAPLIGHT THERAPEUTICS, INC. | 2016-11-24 | — | — | US | disclosed |
| US-9403806-B1 | Cognition enhancing compounds and compositions, methods of making, and methods of treating | NEUROSOLIS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160199356-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | MAPLIGHT THERAPEUTICS, INC. | 2016-07-14 | — | — | US | disclosed |
| US-9174972-B2 | Cognition enhancing compounds and compositions, methods of making, and methods of treating | NEUROSOLIS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150099765-A1 | Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating | NEUROSOLIS INC (US) | 2015-04-09 | — | — | US | disclosed |
| US-8981084-B2 | Oxadiazole HDAC inhibitors | TEMPERO PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8853219-B2 | Compounds and compositions for cognition-enhancement, methods of making, and methods of treating | NEUROSOLIS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-20130274299-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | MAPLIGHT THERAPEUTICS, INC. | 2013-10-17 | — | — | US | disclosed |
| EP-2523664-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2012-11-21 | — | — | EP | disclosed |
| EP-2523944-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | Mithridion, Inc. (US) | 2012-11-21 | — | — | EP | disclosed |
| US-20120289495-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals Inc. | 2012-11-15 | — | — | US | disclosed |
| US-20120046273-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MITHRIDION, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| EP-2403340-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | Mithridion, Inc. (US) | 2012-01-11 | — | — | EP | disclosed |
| US-20110263613-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MAPLIGHT THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| WO-2011088192-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011085406-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MITHRIDION, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2010102218-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MITHRIDION, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
| WO-2003062232-A1 | DERIVATIVES OF THIAZOLES USED FOR THE TREATMENT OF NEUROLOGICAL DISEASES | SOCIETE DE CONSEILS DE RECHERCHE ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340348-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | CHRM3, CHRM4, CHRM5 | ALDH1A1 2646/4885MAPK1 1948/4885LMNA 3708/4885 |
| US-20120046273-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | CHRM3, CHRM4, CHRM5 | ALDH1A1 3256/4885MAPK1 1829/4885LMNA 3321/4885 |
| US-20130274299-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | CHRM3, CHRM4, CHRM5 | ALDH1A1 2646/4885MAPK1 1948/4885LMNA 3708/4885 |
| US-20150099765-A1 | Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating | CHRM3, ACHE, CHRM4 | ALDH1A1 2398/4885MAPK1 2773/4885LMNA 4269/4885 |
| US-20110263613-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | CHRM3, ACHE, CHRM4 | ALDH1A1 2398/4885MAPK1 2773/4885LMNA 4269/4885 |
| US-20160199356-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | CHRM3, CHRM4, CHRM5 | ALDH1A1 2646/4885MAPK1 1948/4885LMNA 3708/4885 |
| US-20120289495-A1 | COMPOUNDS AND METHODS | XDH, CCNY, TOP2B | ALDH1A1 1319/4885MAPK1 4174/4885LMNA 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.